Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by Blue Owl Capital Holdings LP

Blue Owl Capital Holdings LP lifted its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 97.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 242,633 shares of the company's stock after purchasing an additional 120,000 shares during the quarter. Keros Therapeutics comprises approximately 0.9% of Blue Owl Capital Holdings LP's holdings, making the stock its 24th largest holding. Blue Owl Capital Holdings LP owned approximately 0.60% of Keros Therapeutics worth $3,841,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. AlphaQuest LLC grew its holdings in shares of Keros Therapeutics by 469.0% during the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock worth $57,000 after purchasing an additional 2,964 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Keros Therapeutics during the 4th quarter worth approximately $90,000. Exchange Traded Concepts LLC acquired a new position in Keros Therapeutics during the 4th quarter worth approximately $99,000. CANADA LIFE ASSURANCE Co lifted its position in Keros Therapeutics by 207.8% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company's stock worth $116,000 after acquiring an additional 4,976 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in Keros Therapeutics by 19.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock worth $136,000 after acquiring an additional 1,372 shares in the last quarter. Hedge funds and other institutional investors own 71.56% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Wedbush reissued a "neutral" rating and set a $15.00 price target on shares of Keros Therapeutics in a research report on Tuesday, April 1st. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Oppenheimer reduced their price target on Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating on the stock in a research report on Thursday, January 16th. Truist Financial reduced their price target on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Finally, Scotiabank cut their target price on Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating on the stock in a research report on Thursday, January 16th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $40.33.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS traded up $0.19 during trading on Tuesday, reaching $14.45. The stock had a trading volume of 254,951 shares, compared to its average volume of 799,367. Keros Therapeutics, Inc. has a one year low of $9.12 and a one year high of $72.37. The stock has a market cap of $586.83 million, a PE ratio of -2.78 and a beta of 1.39. The firm's 50 day moving average price is $11.63 and its two-hundred day moving average price is $27.13.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. On average, research analysts expect that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Insider Activity

In related news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the purchase, the insider now directly owns 4,392,737 shares in the company, valued at $44,498,425.81. This represents a 27.01 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 22.90% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.